Ars Arthro AG
This article was originally published in Start Up
Ars Arthro's technology, called CaReS, is a cartilage regeneration system that uses harvested cartilage cells which are isolated, then immediately imbedded in a collagen matrix, and then incubated to create a replacement product that can be shaped or molded by surgeons for a precise fit to fix cartilage defects.
You may also be interested in...
Ars Arthro: Taking Tissue Engineering one Step at a Time
Tissue engineering is one of the most promising technology opportunities in orthopedics. But for the companies that have pursued it, the biological process has become something of a waiting game.
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Medical Device Start-Ups in Germany
Despite the important role that French, German, and other European physicians play in developing and trialing new technology, and the equally important role that EU regulators play in offering a quick path to commercialization, the number of native European medical device companies is surprisingly small. There are hints that the bleak devicie picture might be brightening, however.